Dr. Steve Perkins, MD

Dr. Perkins practices at Texas Oncology PA in Irving, Texas.

Dr. Perkins' NPI, 1790780500, was assigned on June 17, 2005. Dr. Perkins graduated from University of the Witwatersrand in 1978. Dr. Perkins holds Texas license G9925.

Dr. Perkins' primary practice is Texas Oncology PA, at 2021 N Macarthur Blvd, Irving, TX 75061 in Dallas County. The practice phone is (972) 997-8000.

Dr. Perkins' primary practice is Texas Oncology PA in Irving, Texas. Dr. Perkins is also affiliated with Baylor Scott & White Medical Center - Irving. The medical group on file is Texas Oncology. Dmand AI also links Dr. Perkins to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Perkins practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Perkins' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Perkins is board certified in hematology by the American Board of Internal Medicine. Dr. Perkins is licensed in Texas.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), lung cancer and lymphoma among the conditions Dr. Perkins treats.

CMS data shows 64,944 Medicare services from Dr. Perkins across 54 procedure codes in 2024, for 367 Medicare patients. Medicare paid $1,124,911 for them. Every service was in an office.

CMS counts 367 Medicare patients who saw Dr. Perkins in 2024. The largest group is 65 to 74, with 171 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 3% are also on Medicaid. Their average risk score is 1.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Perkins' median patient age at 70, with 48% women.

In 2024, Dr. Perkins wrote 2,144 Medicare Part D claims for 278 patients. 76% of them were for generic drugs. CMS names the drug for 1,678 of them, across 54 drugs with 11 or more claims each, at $2,822,703 in total drug cost. In 2023, CMS named 1,498 claims across 54 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Dr. Perkins for performance year 2024, reported through an alternative payment model (APM). Dr. Perkins accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Perkins as offering telehealth.

Dmand AI links 5 papers to Dr. Perkins, published from 2004 to 2014. The most frequent topics are Carcinoma, Squamous Cell and Immunohistochemistry. Dr. Perkins' most frequent co-authors are John M. Truelson, MD, Raheela Ashfaq, FACP, MD and Peter D. Beitsch, MD.

CMS Open Payments shows 154 general payments to Dr. Perkins from 38 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 58% of the total. Merck Sharp & Dohme Corporation paid the most, $8,039.

Dmand AI lists 4 awards for Dr. Perkins, most recently Regional Top Doctor in 2014.

Dr. Perkins graduated from University of the Witwatersrand in 1978. Dr. Perkins is a member of ASCO.

Dr. Perkins is in network with 21 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.